Inovio Pharmaceuticals

INO

Market cap $113M

NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Inovio Pharmaceuticals, Inc. (“Inovio” or the “Company”) (NASDAQ: INO). Such investors are advised to contact Danielle Peyton at  newaction@pomlaw.com  or 646-581-9980, ext. 7980.

I believe Inovio Pharmaceuticals' upside rests almost entirely on INO-3107. The FDA set a standard-review PDUFA for October 30, 2026. INO-3107 targets HPV-6/11 RRP, aiming to reduce repeat surgeries by inducing HPV-specific T-cell responses and addressing the disease's underlying causes. But the FDA questioned INO-3107's accelerated approval. I think this increases the risk of longer timelines with larger confirmatory requirements.

NEW YORK, Jan. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Inovio Pharmaceuticals, Inc. ("Inovio" or the "Company") (NASDAQ: INO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Inovio Pharmaceuticals, Inc. (“Inovio” or the “Company”) (NASDAQ: INO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com  or 646-581-9980, ext. 7980.

NEW YORK, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Inovio Pharmaceuticals, Inc. (“Inovio” or the “Company”) (NASDAQ: INO). Such investors are advised to contact Danielle Peyton at  newaction@pomlaw.com  or 646-581-9980, ext. 7980.

PLYMOUTH MEETING, Pa. , Dec. 29, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) accepted the company's Biologics License Application (BLA) for INO-3107 for review as a potential treatment for adults with RRP.

PLYMOUTH MEETING, Pa. , Dec. 19, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it has made an equity grant to a newly hired employee under its 2022 Inducement Plan (the "Inducement Plan").

Inovio Pharmaceuticals, Inc. (INO) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

PLYMOUTH MEETING, Pa. , Nov. 18, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases, today announced that it will participate in the following investor conferences: Piper Sandler 37th Annual Healthcare Conference (New York, NY) Date: Tuesday, December 2 Time: 8:30-8:55 AM ET Format: Fireside Chat Webcast:  https://bit.ly/44af19l (live webcast and replay available for 90 days after the event) Oppenheimer Movers in Rare Disease Summit (New York, NY) Date: Thursday, December 11 Time: 12:05-12:25 PM ET Format: Panel - Elevator Pitches from Rare Disease Companies with Key Near-Term, Potentially Stock-Moving Catalysts Members of INOVIO's management team will also be conducting one-on-one meetings with investors during these conferences.

Inovio (INO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).